Skip to main content

IQVIA Holdings Value Stock - Dividend - Research Selection

Iqvia s

ISIN: US46266C1053 , WKN: A2JSPM

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


IQVIA Holdings (NYSE:IQV) Partners With SCRI Innovations To Enhance Global Oncology Trials

2025-05-16
IQVIA Holdings (NYSE:IQV) recently announced a collaboration with SCRI Development Innovations to enhance oncology trials globally. However, despite such initiatives, the company's stock price declined by 6% over the past month. This drop comes amid broader market gains, with the S&P 500 rising 4.5% in the past week. Additionally, IQVIA revised its earnings guidance upward and reported mixed Q1 2025 earnings results. These factors, while positive, didn't prevent the stock's decline,...

IQVIA Holdings Inc. stock outperforms competitors on strong trading day

2025-05-16
IQVIA Holdings Inc. stock outperforms competitors on strong trading day

IQVIA and SCRI Collaborate to Accelerate Global Oncology Trials

2025-05-16
RESEARCH TRIANGLE PARK, N.C., May 16, 2025--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, has announced a strategic collaboration with the contract research organization arm of Sarah Cannon Research Institute, SCRI Development Innovations, aimed at transforming oncology trials for biopharma partners worldwide. By combining the capabilities of IQVIA and SCRI Development Inn

3 Dawdling Stocks with Questionable Fundamentals

2025-05-15
Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies.

IQVIA Holdings Inc. stock underperforms Wednesday when compared to competitors

2025-05-14
IQVIA Holdings Inc. stock underperforms Wednesday when compared to competitors

IXJ: Healthcare Sector Dashboard For May

2025-05-14
This article provides a top-down analysis of the healthcare sector using value, quality, and momentum metrics. Read the full analysis here on Seeking Alpha, updated for May 2025.

IQVIA Holdings Inc. stock underperforms Tuesday when compared to competitors

2025-05-13
IQVIA Holdings Inc. stock underperforms Tuesday when compared to competitors

Investing in IQVIA (IQV)? Don't Miss Assessing Its International Revenue Trends

2025-05-13
Evaluate IQVIA's (IQV) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.

IQVIA Holdings Inc. stock underperforms Friday when compared to competitors

2025-05-09
IQVIA Holdings Inc. stock underperforms Friday when compared to competitors

IQVIA: Q1 Earnings Support Steady Optimism

2025-05-09
IQVIA reports strong Q1 earnings with $3.83B revenue & raised guidance.